Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Operating Expenses (2024 - 2025)

Corvus Pharmaceuticals (CRVS) has 2 years of Other Operating Expenses data on record, last reported at -$617000.0 in Q3 2025.

  • For Q3 2025, Other Operating Expenses rose 20.49% year-over-year to -$617000.0; the TTM value through Sep 2025 reached -$2.4 million, down 3.88%, while the annual FY2017 figure was $46.0 million, N/A changed from the prior year.
  • Other Operating Expenses reached -$617000.0 in Q3 2025 per CRVS's latest filing, up from -$848000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at -$551000.0 in Q2 2024 and bottomed at -$994000.0 in Q1 2024.